AstraZeneca PLC (LON: AZN, NASDAQ: AZN) reported better-than-expected second-quarter earnings as strong growth in oncology and rare diseases helped offset weaker sales in other parts of the business.
hVIVO Target Implies 270% Upside as Orderbook More Than Doubles
hVIVO’s order book has more than doubled to £65 million, prompting Shore Capital to reiterate its Buy rating and 25p target price.
hVIVO Orderbook More Than Doubles as Commercial Momentum Rebuilds
hVIVO said its orderbook has more than doubled in the first half of 2026, supported by strong commercial momentum and higher proposal activity.
ImmuPharma appoints Thermo Fisher for drug production
ImmuPharma (AIM: IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished drug form of Kapiglucagon, its experimental diabetes treatment.
Roaring Waters Capital Raises Poolbeg Pharma Stake to 6.55%
Roaring Waters Capital has increased its holding in Poolbeg Pharma, lifting its voting rights to 6.55%. The investor previously held 5.74% of Poolbeg’s voting rights.
Poolbeg Pharma Advances POLB 001 Patent Protection in Israel
Poolbeg Pharma (AIM: POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 patent application covering cancer immunotherapy-induced Cytokine Release Syndrome.
MedPal AI Acquires eMARx to Expand Care Home Medication Platform
MedPal AI (AIM: MPAL) has acquired Solid State Technologies, trading as eMARx, in a deal designed to complete its digital medication platform for the UK care home market.
Poolbeg Pharma Raises £3.5m as Cathal Friel Invests £250,000
Poolbeg Pharma Plc (AIM: POLB) has raised £3.5 million before expenses through the placing of 58,333,328 new shares at 6p each.
Physiomics plc (AIM: PYC) Director Dealing
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the
Genedrive Expects FY26 Income to Rise 40% as NHS Adoption Expands
genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
First patient dosed in POLB 001 TOPICAL trial
First Patient Dosed in the POLB 001 TOPICAL Clinical Trial Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies
Genedrive technology showcased in Parliament
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised